WO2008030344A2 - Implantable apparatus for endolymphatic drug delivery - Google Patents

Implantable apparatus for endolymphatic drug delivery Download PDF

Info

Publication number
WO2008030344A2
WO2008030344A2 PCT/US2007/018631 US2007018631W WO2008030344A2 WO 2008030344 A2 WO2008030344 A2 WO 2008030344A2 US 2007018631 W US2007018631 W US 2007018631W WO 2008030344 A2 WO2008030344 A2 WO 2008030344A2
Authority
WO
WIPO (PCT)
Prior art keywords
catheter
lymphatic
drug
drug delivery
sensing
Prior art date
Application number
PCT/US2007/018631
Other languages
French (fr)
Other versions
WO2008030344A3 (en
Inventor
Allan Shuros
Andrew P. Kramer
Tamara Colette Baynham
James Cawthra
M. Jason Brooke
Original Assignee
Cardiac Pacemakers, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiac Pacemakers, Inc. filed Critical Cardiac Pacemakers, Inc.
Priority to AT07837256T priority Critical patent/ATE545445T1/en
Priority to EP07837256A priority patent/EP2076307B1/en
Priority to AU2007293445A priority patent/AU2007293445A1/en
Priority to JP2009526646A priority patent/JP4987082B2/en
Publication of WO2008030344A2 publication Critical patent/WO2008030344A2/en
Publication of WO2008030344A3 publication Critical patent/WO2008030344A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3613Reperfusion, e.g. of the coronary vessels, e.g. retroperfusion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M25/1011Multiple balloon catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/056Transvascular endocardial electrode systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0043Catheters; Hollow probes characterised by structural features
    • A61M2025/0057Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0043Catheters; Hollow probes characterised by structural features
    • A61M2025/0063Catheters; Hollow probes characterised by structural features having means, e.g. stylets, mandrils, rods or wires to reinforce or adjust temporarily the stiffness, column strength or pushability of catheters which are already inserted into the human body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/04Liquids
    • A61M2202/0405Lymph

Definitions

  • This invention pertains to methods and systems for treating disease with implantable devices.
  • the lymphatic system and the cardiovascular system are closely related structures that are indirectly joined by a capillary system.
  • the lymphatic system is important to the body's defense mechanisms by filtering out organisms that cause disease and by producing lymphocytes that attack foreign organisms and generate antibodies. It is also important for the distribution of fluids and nutrients in the body, because it drains excess fluids and protein from interstitial tissues. Fluid that seeps out of the blood vessels into the interstitial spaces of body tissues and other interstitial components are then absorbed by lymphatic capillaries to form lymph that flows back into the bloodstream through the lymphatic vessels.
  • the terminal structures of the lymphatic vessels include the right lymphatic duct, which drains lymph fluid from the upper right quarter of the body above the diaphragm and down the midline, and the thoracic duct, located in the mediastinum of the pleural cavity which drains the rest of the body.
  • the body Through the flow of blood in and out of arteries, into the veins, and through the lymph vessels and nodes, the body is able to eliminate the products of cellular breakdown and foreign body invasion.
  • an implantable device containing a drug reservoir and control circuitry therefore is connected to a drug delivery catheter that is adapted to be disposed within a lymphatic vessel.
  • the implantable device may also be configured, by means of leads or wirelessly, to receive sensor signals for controlling the delivery of the therapy.
  • the implantable device may also communicate with an external system or external control device via a telemetry link.
  • Fig. 1 shows an exemplary system for therapy delivery via the lymphatic system.
  • Fig. 2 illustrates exemplary components of the electronic circuitry depicted in Fig. 1.
  • Figs. 3 and 4A-B illustrate different embodiments of a drug delivery catheter.
  • Fig. 5 shows an exemplary physical placement of an implantable drug delivery device.
  • Fig. 6 shows an exemplary system for introducing a drug delivery catheter into the lymphatic system.
  • lymphatic vessels are part of the body's circulatory system and serve as a pathway by which fluids can flow from the interstitial spaces into blood. Lymphatic vessels also communicate with lymph nodes and facilitate the body's immune function by transporting foreign antigens to the lymph nodes from the interstitial spaces. With few exceptions, such as the brain and central nervous system, all of the body's tissues communicate with lymphatic vessels. This makes the lymphatic system a convenient conduit for delivering drugs directly to selected internal body locations.
  • an implantable device may be configured with a drug delivery apparatus and a catheter adapted for disposition within a lymphatic vessel that delivers the drug to a target location that is normally drained by the lymphatic vessel.
  • the catheter may be equipped with an inflatable balloon or other occluding structure actuated by the implantable device that blocks the normal antegrade flow of lymphatic fluid and permits the therapeutic agent to be injected into the vessel and flow distally from the balloon and then retrogradely to the target location.
  • Other embodiments may employ no occluding structure and deliver the therapeutic agent so that it flows in an antegrade direction.
  • the device may be further configured with one or more sensing modalities to enable delivery of therapy in accordance with the physiological monitoring and/or with a magnetically or tactilely actuated switch to enable patient control of therapy delivery.
  • the device may also be equipped with wireless telemetry capability to allow control of drug delivery via telemetry commands.
  • Fig. 1 shows an exemplary implantable drug delivery device that includes a delivery catheter adapted for disposition in a lymphatic vessel system to enable drug delivery via the lymphatic system.
  • the implantable drug delivery device 1105 includes a hermetically sealed housing 1130 that may be placed subcutaneously or submuscularly in a patient's chest, similar to a cardiac pacemaker, or other convenient location.
  • the housing 1130 may be formed from a conductive metal, such as titanium, and may additionally serve as an electrode for sensing electrical activity and/or delivering electrical stimulation.
  • the electronic circuitry 1132 Contained within the housing 1130 is the electronic circuitry 1132 which may include a power supply and control circuitry for controlling the operation of the device
  • the electronic circuitry may also include sensing circuitry for sensing physiological variables and a telemetry transceiver for communicating with an external programmer 1190 or other external device such as a remote monitor or a wireless sensor.
  • a header 1140 is mounted on the housing 1130 for receiving a drug delivery catheter 1110 which communicates with a drug delivery apparatus 1200 contained within the housing and controlled by the control circuitry.
  • an inflatable balloon 1111 At the distal end of the catheter 1110 is an inflatable balloon 1111 that may be inflated by a balloon inflation apparatus within the housing through a lumen of the catheter to occlude lymphatic flow as described above.
  • the header may also receive one or more leads 1112 having one or more electrodes or other types of sensors incorporated therein that may be used for sensing a physiological variable such as cardiac electrical activity and controlling the delivery of the drug in accordance therewith.
  • the drug delivery device also incorporates cardiac rhythm management functionality, and a lead may be used to deliver electrical stimulation such as pacing or shock therapy.
  • Fig. 2 illustrates components of the electronic circuitry 1132 and drug delivery apparatus 1200 depicted in Fig. 1 according to one particular embodiment.
  • a controller 1135 is provided which may be made up of discrete circuit elements but is preferably a processing element such as a microprocessor together with associated memory for program and data storage which may be programmed to perform algorithms for delivering therapy. (As the terms are used herein, “circuitry” and “controller” may refer either to a programmed processor or to dedicated hardware components configured to perform a particular task.)
  • the controller is interfaced to the drug delivery apparatus 1200 which communicates with the catheter 1110 to effect delivery of a drug through the catheter to a target location.
  • the drug delivery apparatus is a mechanical pump with a reservoir for containing the drug, where the reservoir may be refillable after implantation. Pumping may also be accomplished in certain embodiments electronically, osmotically, or by electrophoresis.
  • the drug delivered by the device may be any type of therapeutic agent deliverable by the catheter such as a pain relieving agent, a cancer chemotherapeutic agent, an anti-inflammatory agent, an embolizing agent, a cardiac drug, an antibiotic agent, a gene therapeutic agent, and a biological cellular agent.
  • the controller is also interfaced to sensing circuitry 1136 which receives signals generated by one or more sensors 1137.
  • the controller may be configured to control the delivery of drugs by the device in response conditions or events in a closed-loop manner.
  • the sensing circuitry may include, for example, circuitry for amplification, filtering, and/or analog-to-digital conversion of voltages generated by a sensor such as an electrode.
  • the sensor 1137 may be an electrode attached to a lead that can be disposed in the heart for sensing cardiac electrical activity.
  • the sensor 1137 is a lymphatic sensor such as described in co- pending application Serial No. 11/422,417 which may be incorporated into the catheter 1110, or a sensor located on the device housing.. Also interfaced to the controller in Fig.
  • a telemetry transceiver 1150 capable of communicating with an external programmer 1190 or other external device as shown in Fig. 1.
  • An external programmer wirelessly communicates with the device 1105 and enables a clinician to receive data and modify the programming of the controller.
  • a remote monitoring device similarly communicates with the device 1105 and may further interfaced to a network (e.g., an internet connection) for communicating with a patient management server that allows clinical personnel at remote locations to receive data from the remote monitoring device as well as issue commands.
  • the controller may be programmed such that when particular conditions are detected by the sensing circuitry (such as when a measured parameter exceeds or falls below a specified limit value) the device transmits an alarm message to the remote monitoring device and to the patient management server to alert clinical personnel.
  • the telemetry transceiver 1150 allows drug delivery to be initiated or stopped by commands received from an external programmer or other device.
  • the telemetry transceiver may also be used to wirelessly receive signals from other types of physiological monitoring devices.
  • the controller may use such signals to control the delivery of drug therapy in a manner similar to the signals received from a sensor 1137.
  • a tactilely or magnetically actuated switch 1151 that may be used by the patient to initiate or stop the deliver of drug therapy.
  • the controller may be programmed to deliver a specified dosage of the drug upon receiving a command to initiate delivery of drug therapy via the switch 1151.
  • the controller may also be programmed to initiate drug therapy on command only if certain conditions are met such as the total amount of drug delivered over a certain period of time not exceeding a specified limit and one or more sensed physiological variables being within a specified range.
  • the drug delivery catheter 1110 may include an occluding structure an inflatable balloon for blocking the antegrade flow of lymphatic fluid to allow delivery of the drug to the target location in a retrograde direction through the lymphatic vessel.
  • Fig. 2 shows a balloon inflation apparatus 1113 interfaced to the controller that allows the balloon to be inflated during drug delivery through an inflation lumen of the catheter and deflated otherwise to allow normal lymphatic flow.
  • the catheter 1110 in one embodiment may also incorporate plurality of chambers that may be individually pressurized to effect selective stiffening of different portions of the catheter and facilitate passage of the catheter through a lymphatic vessel during implantation.
  • Fig. 3 shows an example of such a catheter 3000 that includes a plurality of pressurizable chambers 3001 each of which communicates with a lumen in the catheter that may be connected to an external pressure source during the implantation procedure.
  • the drug delivery catheter comprises a plurality of concentric layers each of which is selectively permeable to different molecules to enable control of drug flow out of the catheter.
  • Fig. 4A illustrates a partial view of such a catheter showing the outer layer 4001.
  • Fig. 4B illustrates a partial sectional view of the catheter showing the inner layer 4002.
  • a catheter having multiple layers with different permeabilities may also be used in conjunction with a chemosensor to sense the concentrations of different molecules in the lymphatic fluid.
  • Fig. 5 shows an exemplary physical placement within a body 101 of a system 200 for drug delivery via the lymphatic system that includes an implantable drug delivery device 110 that is placed subcutaneously on the patient's chest or abdomen, similar to a standard cardiac pacemaker.
  • the implantable drug delivery device 110 communicates via a telemetry link 125 with an external system 130, such as an external programmer or remote monitoring unit and provides for access to implantable device 110 by a physician or other caregiver.
  • telemetry link 125 is an inductive telemetry link.
  • telemetry link 125 is a far- field radio- frequency (RF) telemetry link. Telemetry link 125 provides for data transmission from implantable device 110 to external system 130.
  • RF radio- frequency
  • Telemetry link 125 also provides for data transmission from external system 130 to implantable medical device 110. This includes, for example, programming implantable device 110 to acquire physiological data, to perform at least one self-diagnostic test (such as for a device operational status), and/or to deliver one or more therapies and/or to adjust the delivery of one or more therapies.
  • the implantable drug delivery device may also incorporate cardiac pacing and/or cardioversion/defibrillation functionality with leads and associated circuitry for that purpose.
  • the implantable device may also be configured to deliver additional therapies such as cardiac ⁇ synchronization therapy (CRT) and cardiac remodeling control therapy (RCT).
  • CRT cardiac ⁇ synchronization therapy
  • RCT cardiac remodeling control therapy
  • the implantable drug delivery device 110 in this embodiment is connected to a drug delivery catheter 112, having a distal member that may incorporate a balloon or other structure for occluding a lymphatic vessel as described above.
  • the catheter 112 passes subcutaneously from the device 110 to a point of venous access in the upper chest or neck such as the subclavian vein. As described below, the catheter may be positioned within the lymphatic system using a venous approach which involves initial entry into the venous blood system.
  • FIG. 5 also illustrates portions of the lymphatic and venous system including portions of thoracic duct 105, a subclavian vein 102, a left external jugular vein 103, and a left internal jugular vein 104.
  • Thoracic duct 105 connects to subclavian vein 102 at the juncture of subclavian vein 102 and a left internal jugular vein 104. Lymphatic fluid from the lower body flows up to thoracic duct 105 and empties into the subclavian vein 102 from thoracic duct 105.
  • the thoracic duct 105 is located in the posterior mediastinal area of the body 101, which is adjacent to the heart and includes various portions of the nervous system including portions of the vagus, sympathetic, and phrenic nerves. Thoracic duct 105 can also be used as a conduit for advancing the drug delivery catheter to a location in a lymphatic vessel from which a drug can be delivered to a target region of the body 101. Electrodes or other sensors incorporated into the catheter 112 may also be used to sense neural activity as well other physiological signals.
  • Catheter 112 includes a proximal end 114, a distal end 116, and an elongate catheter body 118 between proximal end 114 and distal end 116.
  • Proximal end 114 is coupled to the implantable device 110.
  • Distal end 116 includes at least one drug delivery port through which a drug may be injected into a lymphatic vessel.
  • distal end 116 also includes electrodes 120 and 122 for sensing and/or stimulation.
  • the implantable device 110 may include a hermetically sealed conductive housing that functions as a reference electrode.
  • distal end 116 is inserted into subclavian vein 102 through an incision, advanced in subclavian vein 102 toward thoracic duct 105, inserted into thoracic duct 105 from subclavian vein 102, and advanced in thoracic duct 105 until a predetermined location in thoracic duct 105 or a lymphatic vessel communicating with the thoracic duct is reached.
  • an additional lead 232 that includes a proximal end 234, a distal end 236, and an elongate lead body 238 between proximal end 234 and distal end 236.
  • the lead 232 may be configured for subcutaneous placement, external to thoracic duct 105.
  • Proximal end 234 is coupled to implantable device 110, and, in this embodiment, distal end 236 includes an electrode 240 that may be used for sensing and/or stimulation or for use as a reference electrode with any of the other electrodes of the implantable device 110.
  • the system and method described above for delivering agents via the lymphatic system makes use of an implantable device to delivery therapy on a more or less chronic basis.
  • a similar catheter system may be used to deliver agents in an acute setting as well where an external device rather than an implantable device is used to deliver the agent through the catheter.
  • a one-time use catheter is positioned strategically in a lymphatic vessel.
  • the distal tip may be configured to occlude normal lymphatic flow by either lodging in a smaller vessel or employing a balloon structure to inflate and occlude flow.
  • the catheter is removed.
  • This acute catheter system may be used, for example, to inject embolic material into portions of the thoracic duct that are ruptured and causing chylothorax. This condition sometimes occurs following thoracic surgery.
  • the acute catheter system may also be used to locally treat lymphomas where it is used to inject chemotherapy directly to the tumor
  • the lymphatic system may be visualized using lymphangiograpy.
  • lymphatic system drains the dye making the lymphatic vessels visible.
  • a lymphatic vessel is cannulated, and radiopaque contrast is injected to illuminate major lymph vessels including the thoracic duct and its ostium into the subclavian vein.
  • the catheter may then be guided into the thoracic duct ostium via the venous system using fluoroscopy techniques and positioned at a selected location within the lymphatic system.
  • Initial cannulation of the lymph ostium may be achieved through the left or right subclavian vein, the left jugular veins, or the femoral veins.
  • an overlapping technique may be employed whereby fluoroscopic images produced by the injected dye are used in conjunction with anatomical images of the patient produced by other modalities such as conventional x-ray, CAT scans, MRI scans, or ultrasonic scans.
  • the fluoroscopic image may be overlaid with the anatomical image and the catheter then guided to the selected location.
  • the catheter may be introduced into the venous system and from there into the thoracic duct ostium using conventional over-the-wire techniques that employ a guide wire.
  • the guide wire is manually or mechanically pushed and manipulated to guide its travel and upon which catheters and/or leads may be advanced.
  • a catheter having multiple pressurizable chambers such as described above may also be used to selectively stiffen portions of the catheter during implantation.
  • a stereotaxis technique in which external magnets or other means are used to guide the catheter may also be used to improve maneuverability and precision as well as provide increased safety.
  • An example of this technique is described in U.S. Patent No. 6,475,223, hereby incorporated by reference.
  • An alternative technique for opening lymphatic valves involves using a catheter incorporating a compliant balloon on its distal tip.
  • the balloon is inflated to mechanically dilate the vessel which opens the valve and allows a wire or the catheter to pass through. This may be the same balloon used to occlude lymphatic flow during drug delivery as described above.
  • the catheter incorporates an electrode at its tip (which may or may not be a lymphatic instrument intended to be left in the lymphatic vessel) that is used to cause smooth muscle contraction of the lymphatic vessel. Such smooth muscle contraction can create a pressure gradient that opens the valve and allows the catheter to advance past the valve.
  • Fig. 6 shows an exemplary system for introducing a drug delivery catheter into the lymphatic system using the techniques described above.
  • a system in accordance with the invention may have any or all of the components depicted in the figure.
  • a workstation 601 is a computer in communication with the other system
  • the workstation provides an output for actuating the catheter controller 605 that mechanically pushes a drug delivery catheter 651 into the lymphatic system of patient 650.
  • An electro-stimulator 606 and vacuum actuator 607 are also interfaced to the workstation for facilitating passage of the catheter 651 through valves in the lymph vessels.
  • the electro-stimulator provides electrical energy to an electrode of the catheter 651 in order to cause contraction of smooth muscle in the lymphatic vessel walls and create a pressure gradient to open lymphatic valves.
  • the vacuum actuator 607 draws a vacuum through a lumen of the catheter 651 in order to open lymphatic valves.
  • the system also has the capability for magnetically guiding a ferrromagnetic tip of the catheter 651 (or guide wire) by means of movable guiding magnets 611, and a magnet actuator 610 is interfaced to the workstation for this purpose.
  • a fluoroscope 620 is interfaced to the workstation. When the patient's lymphatic system is injected with a radio-opaque dye through a port of the catheter, the fluoroscope provides images of the lymphatic vessels as the catheter travels therethrough.
  • the workstation is also interfaced to an image repository 630 that stores images of the patient's anatomy obtained with one or more other imaging modalities such as conventional x-ray, CAT, MRI, and ultrasound.
  • the operator may overlap an image from the image respository with the fluoroscopic image in order to provide anatomical landmarks for guiding the catheter to a selected location in the patient's body.

Abstract

Described herein are a method and apparatus for introducing instrumentation like an implantable drug delivery apparatus (1200) with a balloon catheter (1111) and sensors into the lymphatic system. It can be used for physiological monitoring and/or delivery of therapy. Such instrumentation, for example, may include one or more sensors for measuring physiological variables and/or one or more instruments for delivering therapy that is adapted to be disposed within a lymphatic vessel.

Description

APPARATUS FOR ENDOLYMPHATIC DRUG DELIVERY
CLAIM OF PRIORITY
Benefit of priority is hereby claimed to U.S. Patent Application Serial Number 11/469,793, filed September 1, 2006, which application is herein incorporated by reference.
RELATED APPLICATIONS
This application is related to co-pending application Ser. Nos.
11/422,414, filed on June 6, 2006 (Attorney Docket No. 279.A04US1);
11/422,417, filed on June 6, 2006 (Attorney Docket No. 279.A05US1);
11/422,418, filed on June 6, 2006 (Attorney Docket No. 279.A66US1); 11/422,421, filed on June 6, 2006 (Attorney Docket No. 279.A68US1) and
11/422,423, filed on June 6, 2006 (Attorney Docket No. 279.A69US1), the disclosures of which are hereby incorporated by reference.
FIELD OF THE INVENTION This invention pertains to methods and systems for treating disease with implantable devices.
BACKGROUND The lymphatic system and the cardiovascular system are closely related structures that are indirectly joined by a capillary system. The lymphatic system is important to the body's defense mechanisms by filtering out organisms that cause disease and by producing lymphocytes that attack foreign organisms and generate antibodies. It is also important for the distribution of fluids and nutrients in the body, because it drains excess fluids and protein from interstitial tissues. Fluid that seeps out of the blood vessels into the interstitial spaces of body tissues and other interstitial components are then absorbed by lymphatic capillaries to form lymph that flows back into the bloodstream through the lymphatic vessels. The terminal structures of the lymphatic vessels include the right lymphatic duct, which drains lymph fluid from the upper right quarter of the body above the diaphragm and down the midline, and the thoracic duct, located in the mediastinum of the pleural cavity which drains the rest of the body. Through the flow of blood in and out of arteries, into the veins, and through the lymph vessels and nodes, the body is able to eliminate the products of cellular breakdown and foreign body invasion.
SUMMARY
Described herein are a method and apparatus for delivering a drug to internal body locations via the lymphatic system. In one embodiment, an implantable device containing a drug reservoir and control circuitry therefore is connected to a drug delivery catheter that is adapted to be disposed within a lymphatic vessel. The implantable device may also be configured, by means of leads or wirelessly, to receive sensor signals for controlling the delivery of the therapy. The implantable device may also communicate with an external system or external control device via a telemetry link.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows an exemplary system for therapy delivery via the lymphatic system.
Fig. 2 illustrates exemplary components of the electronic circuitry depicted in Fig. 1.
Figs. 3 and 4A-B illustrate different embodiments of a drug delivery catheter. Fig. 5 shows an exemplary physical placement of an implantable drug delivery device.
Fig. 6 shows an exemplary system for introducing a drug delivery catheter into the lymphatic system.
DETAILED DESCRIPTION
The lymphatic vessels are part of the body's circulatory system and serve as a pathway by which fluids can flow from the interstitial spaces into blood. Lymphatic vessels also communicate with lymph nodes and facilitate the body's immune function by transporting foreign antigens to the lymph nodes from the interstitial spaces. With few exceptions, such as the brain and central nervous system, all of the body's tissues communicate with lymphatic vessels. This makes the lymphatic system a convenient conduit for delivering drugs directly to selected internal body locations. (As the term is used herein, a drug is any chemical or biological substance intended to have a therapeutic or diagnostic effect.) As described below, an implantable device may be configured with a drug delivery apparatus and a catheter adapted for disposition within a lymphatic vessel that delivers the drug to a target location that is normally drained by the lymphatic vessel. The catheter may be equipped with an inflatable balloon or other occluding structure actuated by the implantable device that blocks the normal antegrade flow of lymphatic fluid and permits the therapeutic agent to be injected into the vessel and flow distally from the balloon and then retrogradely to the target location. Other embodiments may employ no occluding structure and deliver the therapeutic agent so that it flows in an antegrade direction. The device may be further configured with one or more sensing modalities to enable delivery of therapy in accordance with the physiological monitoring and/or with a magnetically or tactilely actuated switch to enable patient control of therapy delivery. The device may also be equipped with wireless telemetry capability to allow control of drug delivery via telemetry commands.
Fig. 1 shows an exemplary implantable drug delivery device that includes a delivery catheter adapted for disposition in a lymphatic vessel system to enable drug delivery via the lymphatic system. The implantable drug delivery device 1105 includes a hermetically sealed housing 1130 that may be placed subcutaneously or submuscularly in a patient's chest, similar to a cardiac pacemaker, or other convenient location. The housing 1130 may be formed from a conductive metal, such as titanium, and may additionally serve as an electrode for sensing electrical activity and/or delivering electrical stimulation. Contained within the housing 1130 is the electronic circuitry 1132 which may include a power supply and control circuitry for controlling the operation of the device
(e.g., a programmable electronic controller or other types of logic circuitry). The electronic circuitry may also include sensing circuitry for sensing physiological variables and a telemetry transceiver for communicating with an external programmer 1190 or other external device such as a remote monitor or a wireless sensor. A header 1140 is mounted on the housing 1130 for receiving a drug delivery catheter 1110 which communicates with a drug delivery apparatus 1200 contained within the housing and controlled by the control circuitry. At the distal end of the catheter 1110 is an inflatable balloon 1111 that may be inflated by a balloon inflation apparatus within the housing through a lumen of the catheter to occlude lymphatic flow as described above. The header may also receive one or more leads 1112 having one or more electrodes or other types of sensors incorporated therein that may be used for sensing a physiological variable such as cardiac electrical activity and controlling the delivery of the drug in accordance therewith. In certain embodiments, the drug delivery device also incorporates cardiac rhythm management functionality, and a lead may be used to deliver electrical stimulation such as pacing or shock therapy.
Fig. 2 illustrates components of the electronic circuitry 1132 and drug delivery apparatus 1200 depicted in Fig. 1 according to one particular embodiment. A controller 1135 is provided which may be made up of discrete circuit elements but is preferably a processing element such as a microprocessor together with associated memory for program and data storage which may be programmed to perform algorithms for delivering therapy. (As the terms are used herein, "circuitry" and "controller" may refer either to a programmed processor or to dedicated hardware components configured to perform a particular task.) The controller is interfaced to the drug delivery apparatus 1200 which communicates with the catheter 1110 to effect delivery of a drug through the catheter to a target location. In one embodiment, the drug delivery apparatus is a mechanical pump with a reservoir for containing the drug, where the reservoir may be refillable after implantation. Pumping may also be accomplished in certain embodiments electronically, osmotically, or by electrophoresis. As aforesaid, the drug delivered by the device may be any type of therapeutic agent deliverable by the catheter such as a pain relieving agent, a cancer chemotherapeutic agent, an anti-inflammatory agent, an embolizing agent, a cardiac drug, an antibiotic agent, a gene therapeutic agent, and a biological cellular agent. The controller is also interfaced to sensing circuitry 1136 which receives signals generated by one or more sensors 1137. The controller may be configured to control the delivery of drugs by the device in response conditions or events in a closed-loop manner. The sensing circuitry may include, for example, circuitry for amplification, filtering, and/or analog-to-digital conversion of voltages generated by a sensor such as an electrode. As discussed above, in certain embodiments, the sensor 1137 may be an electrode attached to a lead that can be disposed in the heart for sensing cardiac electrical activity. In other embodiments, the sensor 1137 is a lymphatic sensor such as described in co- pending application Serial No. 11/422,417 which may be incorporated into the catheter 1110, or a sensor located on the device housing.. Also interfaced to the controller in Fig. 2 is a telemetry transceiver 1150 capable of communicating with an external programmer 1190 or other external device as shown in Fig. 1. An external programmer wirelessly communicates with the device 1105 and enables a clinician to receive data and modify the programming of the controller. In the case where the device 1105 has sensing capability, a remote monitoring device similarly communicates with the device 1105 and may further interfaced to a network (e.g., an internet connection) for communicating with a patient management server that allows clinical personnel at remote locations to receive data from the remote monitoring device as well as issue commands. The controller may be programmed such that when particular conditions are detected by the sensing circuitry (such as when a measured parameter exceeds or falls below a specified limit value) the device transmits an alarm message to the remote monitoring device and to the patient management server to alert clinical personnel.
The telemetry transceiver 1150 allows drug delivery to be initiated or stopped by commands received from an external programmer or other device. The telemetry transceiver may also be used to wirelessly receive signals from other types of physiological monitoring devices. The controller may use such signals to control the delivery of drug therapy in a manner similar to the signals received from a sensor 1137. Also interfaced to the controller in Fig. 2 is a tactilely or magnetically actuated switch 1151 that may be used by the patient to initiate or stop the deliver of drug therapy. In certain embodiments, the controller may be programmed to deliver a specified dosage of the drug upon receiving a command to initiate delivery of drug therapy via the switch 1151. The controller may also be programmed to initiate drug therapy on command only if certain conditions are met such as the total amount of drug delivered over a certain period of time not exceeding a specified limit and one or more sensed physiological variables being within a specified range. In certain embodiments, such as that illustrated in Fig. 1 , the drug delivery catheter 1110 may include an occluding structure an inflatable balloon for blocking the antegrade flow of lymphatic fluid to allow delivery of the drug to the target location in a retrograde direction through the lymphatic vessel. Fig. 2 shows a balloon inflation apparatus 1113 interfaced to the controller that allows the balloon to be inflated during drug delivery through an inflation lumen of the catheter and deflated otherwise to allow normal lymphatic flow. Other embodiments may employ no occluding structure or may employ another type of actuated or passive occluding structure such as a tapered tip that is intubated within a lymph vessel to occlude flow. The catheter 1110 in one embodiment may also incorporate plurality of chambers that may be individually pressurized to effect selective stiffening of different portions of the catheter and facilitate passage of the catheter through a lymphatic vessel during implantation. Fig. 3 shows an example of such a catheter 3000 that includes a plurality of pressurizable chambers 3001 each of which communicates with a lumen in the catheter that may be connected to an external pressure source during the implantation procedure. In another embodiment, the drug delivery catheter comprises a plurality of concentric layers each of which is selectively permeable to different molecules to enable control of drug flow out of the catheter. Fig. 4A illustrates a partial view of such a catheter showing the outer layer 4001. Fig. 4B illustrates a partial sectional view of the catheter showing the inner layer 4002. A catheter having multiple layers with different permeabilities may also be used in conjunction with a chemosensor to sense the concentrations of different molecules in the lymphatic fluid.
Fig. 5 shows an exemplary physical placement within a body 101 of a system 200 for drug delivery via the lymphatic system that includes an implantable drug delivery device 110 that is placed subcutaneously on the patient's chest or abdomen, similar to a standard cardiac pacemaker. The implantable drug delivery device 110 communicates via a telemetry link 125 with an external system 130, such as an external programmer or remote monitoring unit and provides for access to implantable device 110 by a physician or other caregiver. In one embodiment, telemetry link 125 is an inductive telemetry link. In another embodiment, telemetry link 125 is a far- field radio- frequency (RF) telemetry link. Telemetry link 125 provides for data transmission from implantable device 110 to external system 130. This includes, for example, transmitting real-time physiological data acquired by implantable device 110, extracting physiological data acquired by and stored in implantable device 110, extracting patient history data such as occurrences of predetermined types of pathological events and therapy deliveries recorded in implantable device 110, and/or extracting data indicating an operational status of implantable device 110 (e.g., battery status and lead impedance). Telemetry link 125 also provides for data transmission from external system 130 to implantable medical device 110. This includes, for example, programming implantable device 110 to acquire physiological data, to perform at least one self-diagnostic test (such as for a device operational status), and/or to deliver one or more therapies and/or to adjust the delivery of one or more therapies. In certain embodiments, the implantable drug delivery device may also incorporate cardiac pacing and/or cardioversion/defibrillation functionality with leads and associated circuitry for that purpose. The implantable device may also be configured to deliver additional therapies such as cardiac ^synchronization therapy (CRT) and cardiac remodeling control therapy (RCT).
The implantable drug delivery device 110 in this embodiment is connected to a drug delivery catheter 112, having a distal member that may incorporate a balloon or other structure for occluding a lymphatic vessel as described above. The catheter 112 passes subcutaneously from the device 110 to a point of venous access in the upper chest or neck such as the subclavian vein. As described below, the catheter may be positioned within the lymphatic system using a venous approach which involves initial entry into the venous blood system.
FIG. 5 also illustrates portions of the lymphatic and venous system including portions of thoracic duct 105, a subclavian vein 102, a left external jugular vein 103, and a left internal jugular vein 104. Thoracic duct 105 connects to subclavian vein 102 at the juncture of subclavian vein 102 and a left internal jugular vein 104. Lymphatic fluid from the lower body flows up to thoracic duct 105 and empties into the subclavian vein 102 from thoracic duct 105. The thoracic duct 105 is located in the posterior mediastinal area of the body 101, which is adjacent to the heart and includes various portions of the nervous system including portions of the vagus, sympathetic, and phrenic nerves. Thoracic duct 105 can also be used as a conduit for advancing the drug delivery catheter to a location in a lymphatic vessel from which a drug can be delivered to a target region of the body 101. Electrodes or other sensors incorporated into the catheter 112 may also be used to sense neural activity as well other physiological signals.
Catheter 112 includes a proximal end 114, a distal end 116, and an elongate catheter body 118 between proximal end 114 and distal end 116. Proximal end 114 is coupled to the implantable device 110. Distal end 116 includes at least one drug delivery port through which a drug may be injected into a lymphatic vessel. In the embodiment illustrated in FIG. 5, distal end 116 also includes electrodes 120 and 122 for sensing and/or stimulation. The implantable device 110 may include a hermetically sealed conductive housing that functions as a reference electrode. During the implantation of catheter 112, distal end 116 is inserted into subclavian vein 102 through an incision, advanced in subclavian vein 102 toward thoracic duct 105, inserted into thoracic duct 105 from subclavian vein 102, and advanced in thoracic duct 105 until a predetermined location in thoracic duct 105 or a lymphatic vessel communicating with the thoracic duct is reached. Also shown in the illustrated embodiment is an additional lead 232 that includes a proximal end 234, a distal end 236, and an elongate lead body 238 between proximal end 234 and distal end 236. The lead 232 may be configured for subcutaneous placement, external to thoracic duct 105. Proximal end 234 is coupled to implantable device 110, and, in this embodiment, distal end 236 includes an electrode 240 that may be used for sensing and/or stimulation or for use as a reference electrode with any of the other electrodes of the implantable device 110. The system and method described above for delivering agents via the lymphatic system makes use of an implantable device to delivery therapy on a more or less chronic basis. A similar catheter system may be used to deliver agents in an acute setting as well where an external device rather than an implantable device is used to deliver the agent through the catheter. In this embodiment, a one-time use catheter is positioned strategically in a lymphatic vessel. The distal tip may be configured to occlude normal lymphatic flow by either lodging in a smaller vessel or employing a balloon structure to inflate and occlude flow. After the agents have been deployed in the lymphatic vessel(s) the catheter is removed. This acute catheter system may be used, for example, to inject embolic material into portions of the thoracic duct that are ruptured and causing chylothorax. This condition sometimes occurs following thoracic surgery. The acute catheter system may also be used to locally treat lymphomas where it is used to inject chemotherapy directly to the tumor In order to implant a drug delivery catheter into a selected location within lymphatic vessel, the lymphatic system may be visualized using lymphangiograpy. hi this technique, dye is injected into the subcutaneous tissue of an extremity such as the foot, or other peripheral lymph vessel, and the lymphatic system drains the dye making the lymphatic vessels visible. A lymphatic vessel is cannulated, and radiopaque contrast is injected to illuminate major lymph vessels including the thoracic duct and its ostium into the subclavian vein. The catheter may then be guided into the thoracic duct ostium via the venous system using fluoroscopy techniques and positioned at a selected location within the lymphatic system. Initial cannulation of the lymph ostium may be achieved through the left or right subclavian vein, the left jugular veins, or the femoral veins. In order to facilitate navigation through the lymphatic vessels and position the catheter at a selected anatomical location, an overlapping technique may be employed whereby fluoroscopic images produced by the injected dye are used in conjunction with anatomical images of the patient produced by other modalities such as conventional x-ray, CAT scans, MRI scans, or ultrasonic scans. The fluoroscopic image may be overlaid with the anatomical image and the catheter then guided to the selected location. The catheter may be introduced into the venous system and from there into the thoracic duct ostium using conventional over-the-wire techniques that employ a guide wire. The guide wire is manually or mechanically pushed and manipulated to guide its travel and upon which catheters and/or leads may be advanced. A catheter having multiple pressurizable chambers such as described above may also be used to selectively stiffen portions of the catheter during implantation. A stereotaxis technique in which external magnets or other means are used to guide the catheter may also be used to improve maneuverability and precision as well as provide increased safety. An example of this technique is described in U.S. Patent No. 6,475,223, hereby incorporated by reference. Once the catheter is in the lymphatic system, it must also traverse valves in the lymphatic vessels whose function is to allow flow of lymphatic fluid in only one direction to the thoracic duct. As the catheter is guided through a vessel to one of these valves, the catheter may incorporate a vacuum system to open the valves. When the vacuum system is actuated, it draws negative pressure to create a pressure gradient that opens the valve. An alternative technique for opening lymphatic valves involves using a catheter incorporating a compliant balloon on its distal tip. When the catheter reaches a lymphatic valve, the balloon is inflated to mechanically dilate the vessel which opens the valve and allows a wire or the catheter to pass through. This may be the same balloon used to occlude lymphatic flow during drug delivery as described above. In still another technique, the catheter incorporates an electrode at its tip (which may or may not be a lymphatic instrument intended to be left in the lymphatic vessel) that is used to cause smooth muscle contraction of the lymphatic vessel. Such smooth muscle contraction can create a pressure gradient that opens the valve and allows the catheter to advance past the valve.
The implantation of a drug delivery catheter may be performed using the same techniques and apparatus as described in co-pending application Ser. No. 11/422,423 for implanting endolymphatic instrumentation. Fig. 6 shows an exemplary system for introducing a drug delivery catheter into the lymphatic system using the techniques described above. A system in accordance with the invention may have any or all of the components depicted in the figure. A workstation 601 is a computer in communication with the other system
m components and provides a user interface for controlling the operation of the system. The workstation provides an output for actuating the catheter controller 605 that mechanically pushes a drug delivery catheter 651 into the lymphatic system of patient 650. An electro-stimulator 606 and vacuum actuator 607 are also interfaced to the workstation for facilitating passage of the catheter 651 through valves in the lymph vessels. As described above, the electro-stimulator provides electrical energy to an electrode of the catheter 651 in order to cause contraction of smooth muscle in the lymphatic vessel walls and create a pressure gradient to open lymphatic valves. The vacuum actuator 607 draws a vacuum through a lumen of the catheter 651 in order to open lymphatic valves. The system also has the capability for magnetically guiding a ferrromagnetic tip of the catheter 651 (or guide wire) by means of movable guiding magnets 611, and a magnet actuator 610 is interfaced to the workstation for this purpose. In order to provide the operator with information as to the location of the catheter within the lymphatic system, a fluoroscope 620 is interfaced to the workstation. When the patient's lymphatic system is injected with a radio-opaque dye through a port of the catheter, the fluoroscope provides images of the lymphatic vessels as the catheter travels therethrough. The workstation is also interfaced to an image repository 630 that stores images of the patient's anatomy obtained with one or more other imaging modalities such as conventional x-ray, CAT, MRI, and ultrasound. The operator may overlap an image from the image respository with the fluoroscopic image in order to provide anatomical landmarks for guiding the catheter to a selected location in the patient's body.
Although the invention has been described in conjunction with the foregoing specific embodiments, many alternatives, variations, and modifications will be apparent to those of ordinary skill in the art. Such alternatives, variations, and modifications are intended to fall within the scope of the following appended claims.

Claims

What is claimed is:
1. A device, comprising: an implantable housing; drug delivery apparatus contained within the implantable housing; a catheter adapted for disposition within a lymphatic vessel and having a lumen communicating with the drug delivery apparatus; an occluding structure incorporated into the catheter for blocking flow of lymphatic fluid in the lymphatic vessel; control circuitry contained within the implantable housing for controlling operation of the occluding structure and drug delivery apparatus to enable delivery of a drug out of the catheter distally from the occluding structure and into the lymphatic vessel.
2. The device of claim 1 wherein the occluding structure is an inflatable balloon mounted on the catheter and further comprising an inflation apparatus contained within the implantable housing for inflating the balloon through a balloon inflation lumen of the catheter.
3. The device of claims 1 or 2 wherein the catheter incorporates a plurality of chambers that may be individually pressurized to effect selective stiffening of different portions of the catheter and facilitate passage of the catheter through a lymphatic vessel.
4. The device of any of claims 1 through 3 wherein the catheter comprises a plurality of concentric layers each of which is selectively permeable to different molecules to enable control of drug flow out of the catheter.
5. The device of any of claims 1 through 4 wherein the drug delivery apparatus is a mechanical pump connected to a drug reservoir.
19
6. The device of any of claims 1 through 5 further comprising sensing circuitry for sensing a physiological signal and wherein the control circuitry is configured to deliver the drug in a manner responsive to the physiological signal.
7. The device of claim 6 further comprising an electrode connected to the sensing circuitry by a lead adapted for disposition within the heart and wherein the sensing circuitry is configured to sense cardiac electrical activity.
8. The device of claim 6 further comprising a lymphatic sensor connected to the sensing circuitry for sensing the lymphatic fluid within the lymphatic vessel.
9. The device of any of claims 1 through 8 further comprising a tactilely or magnetically actuated switch operable to initiate or stop delivery of the drug.
10. The device of any of claims 1 through 9 further comprising a telemetry transceiver interfaced to the control circuitry for enabling wireless communication with the device.
PCT/US2007/018631 2006-09-01 2007-08-23 Implantable apparatus for endolymphatic drug delivery WO2008030344A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT07837256T ATE545445T1 (en) 2006-09-01 2007-08-23 IMPLANTABLE DEVICE FOR ADMINISTRATION OF AN ENDOLYMPHATIC ACT
EP07837256A EP2076307B1 (en) 2006-09-01 2007-08-23 Implantable apparatus for endolymphatic drug delivery
AU2007293445A AU2007293445A1 (en) 2006-09-01 2007-08-23 Implantable apparatus for endolymphatic drug delivery
JP2009526646A JP4987082B2 (en) 2006-09-01 2007-08-23 Implantable device for endolymph drug delivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/469,793 US8905999B2 (en) 2006-09-01 2006-09-01 Method and apparatus for endolymphatic drug delivery
US11/469,793 2006-09-01

Publications (2)

Publication Number Publication Date
WO2008030344A2 true WO2008030344A2 (en) 2008-03-13
WO2008030344A3 WO2008030344A3 (en) 2008-05-15

Family

ID=39144611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018631 WO2008030344A2 (en) 2006-09-01 2007-08-23 Implantable apparatus for endolymphatic drug delivery

Country Status (6)

Country Link
US (1) US8905999B2 (en)
EP (1) EP2076307B1 (en)
JP (1) JP4987082B2 (en)
AT (1) ATE545445T1 (en)
AU (1) AU2007293445A1 (en)
WO (1) WO2008030344A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7734341B2 (en) 2006-06-06 2010-06-08 Cardiac Pacemakers, Inc. Method and apparatus for gastrointestinal stimulation via the lymphatic system
US7894906B2 (en) 2006-06-06 2011-02-22 Cardiac Pacemakers, Inc. Amelioration of chronic pain by endolymphatic stimulation
US8126538B2 (en) 2006-06-06 2012-02-28 Cardiac Pacemakers, Inc. Method and apparatus for introducing endolymphatic instrumentation
US8369943B2 (en) 2006-06-06 2013-02-05 Cardiac Pacemakers, Inc. Method and apparatus for neural stimulation via the lymphatic system
US8905999B2 (en) 2006-09-01 2014-12-09 Cardiac Pacemakers, Inc. Method and apparatus for endolymphatic drug delivery
US10376694B2 (en) 2008-10-09 2019-08-13 Virender K. Sharma Method and apparatus for stimulating the vascular system
US10603489B2 (en) 2008-10-09 2020-03-31 Virender K. Sharma Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage
WO2023076259A1 (en) 2021-10-25 2023-05-04 Revere Pharmaceuticals Triazolopyridazine compounds useful as rac1 inhibitors

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007012417D1 (en) 2006-03-14 2011-03-24 Univ Southern California Mems device for drug release
US8579853B2 (en) * 2006-10-31 2013-11-12 Abbott Diabetes Care Inc. Infusion devices and methods
WO2008100974A2 (en) * 2007-02-13 2008-08-21 Sharma Virender K Method and apparatus for electrical stimulation of the pancreatico-biliary system
EP2666510B1 (en) 2007-12-20 2017-10-18 University Of Southern California Apparatus for controlled delivery of therapeutic agents
CN102202719B (en) 2008-05-08 2014-11-26 迷你泵有限责任公司 Implantable pums and cannulas therefor
US8486278B2 (en) 2008-05-08 2013-07-16 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US9849238B2 (en) 2008-05-08 2017-12-26 Minipumps, Llc Drug-delivery pump with intelligent control
US9186512B2 (en) * 2008-09-23 2015-11-17 Cardiac Pacemakers, Inc. Method and apparatus for organ specific inflammation monitoring
WO2010080717A1 (en) 2009-01-12 2010-07-15 The Board Of Trustees Of The Leland Stanford Junior University Drainage device and method
US20100256700A1 (en) * 2009-04-07 2010-10-07 Shuros Allan C Method and apparatus for organ specific inflammation therapy
JP5758388B2 (en) 2009-08-18 2015-08-05 ミニパンプス, エルエルシー Electrolyte drug delivery pump with adaptive control
US10052059B2 (en) 2011-05-03 2018-08-21 Matthew J. Callaghan Apparatus and methods for accessing the lymphatic system
WO2012012406A1 (en) 2010-07-19 2012-01-26 Minipumps, Llc Catheter drug pump
US10111997B2 (en) 2011-05-03 2018-10-30 Matthew J. Callaghan Apparatus and methods for accessing the lymphatic system
US10688236B2 (en) 2013-01-21 2020-06-23 Lxs, Llc Systems and methods for performing medical procedures involving accessing the lymphatic system
WO2014197886A1 (en) * 2013-06-08 2014-12-11 Callaghan Mathew John Systems and methods for performing medical procedures involving accessing the lymphatic system
US9901722B2 (en) 2014-06-01 2018-02-27 White Swell Medical Ltd System and method for treatment of pulmonary edema
WO2016138176A1 (en) 2015-02-24 2016-09-01 Elira Therapeutics Llc Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch
US9956393B2 (en) 2015-02-24 2018-05-01 Elira, Inc. Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch
US10376145B2 (en) 2015-02-24 2019-08-13 Elira, Inc. Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch
US10765863B2 (en) 2015-02-24 2020-09-08 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US10864367B2 (en) 2015-02-24 2020-12-15 Elira, Inc. Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions
US10335302B2 (en) 2015-02-24 2019-07-02 Elira, Inc. Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions
IL294513A (en) 2015-05-11 2022-09-01 White Swell Medical Ltd Systems and methods for reducing pressure at an outflow of a duct
WO2017176776A1 (en) * 2016-04-04 2017-10-12 General Electric Company Techniques for neuromodulation
US10960189B2 (en) 2016-11-01 2021-03-30 White Swell Medical Ltd Systems and methods for treatment of fluid overload
EP4252824A3 (en) 2017-03-02 2023-11-08 White Swell Medical Ltd Systems and methods for reducing pressure at outflow of a duct
EP3600178A4 (en) 2017-03-19 2020-12-02 White Swell Medical Ltd Methods and devices for reducing pressure
US11717674B2 (en) 2018-07-31 2023-08-08 Manicka Institute Llc Subcutaneous device for use with remote device
US11660444B2 (en) 2018-07-31 2023-05-30 Manicka Institute Llc Resilient body component contact for a subcutaneous device
US10576291B2 (en) 2018-07-31 2020-03-03 Manicka Institute Llc Subcutaneous device
US11724095B2 (en) 2019-02-26 2023-08-15 White Swell Medical Ltd Devices and methods for treating edema
US11793996B2 (en) 2019-02-26 2023-10-24 White Swell Medical Ltd Devices and methods for treating edema
US11660426B2 (en) 2019-02-26 2023-05-30 White Swell Medical Ltd Devices and methods for treating edema
US11717652B2 (en) 2019-02-26 2023-08-08 White Swell Medical Ltd Devices and methods for treating edema
JP7249227B2 (en) 2019-07-18 2023-03-30 日本航空電子工業株式会社 aggregate cable

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030036773A1 (en) * 2001-08-03 2003-02-20 Whitehurst Todd K. Systems and methods for treatment of coronary artery disease
WO2004032791A2 (en) * 2002-09-20 2004-04-22 Flowmedica, Inc. Method and apparatus for selective material delivery via an intra-renal catheter
EP1504778A2 (en) * 2003-08-06 2005-02-09 Ethicon Endo-Surgery Implantable pump for the treatment of obesity

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3814080A (en) 1972-11-13 1974-06-04 Becton Dickinson Co Vessel cannulator and clamp for lymphangiography
US3916875A (en) 1974-01-02 1975-11-04 Herbert Toch Lymph duct cannulation facilitator
SU1074527A1 (en) 1981-08-07 1984-02-23 Киевский научно-исследовательский институт клинической и экспериментальной хирургии Method of stimulation of lypmh drainage in external drainage of thoracic duct
JPS60216468A (en) 1984-04-09 1985-10-29 Mitsubishi Electric Corp Fuel cell device
CH668191A5 (en) * 1984-08-22 1988-12-15 Sarcem Sa REMOTE CONTROL CATHETER.
US4909787A (en) * 1986-08-14 1990-03-20 Danforth John W Controllable flexibility catheter with eccentric stiffener
US4792330A (en) 1987-07-13 1988-12-20 Lazarus Medical Innovations, Inc. Combination catheter and duct clamp apparatus and method
CA1327838C (en) 1988-06-13 1994-03-15 Fred Zacouto Implantable device to prevent blood clotting disorders
US4963306A (en) * 1988-07-14 1990-10-16 Novoste Corporation Method for making fuseless soft tip angiographic catheter
US4957484A (en) 1988-07-26 1990-09-18 Automedix Sciences, Inc. Lymph access catheters and methods of administration
US5112303A (en) * 1991-05-02 1992-05-12 Pudenz-Schulte Medical Research Corporation Tumor access device and method for delivering medication into a body cavity
US5231988A (en) 1991-08-09 1993-08-03 Cyberonics, Inc. Treatment of endocrine disorders by nerve stimulation
CA2153993A1 (en) 1992-01-16 1993-08-05 Rakesh K. Jain Method and apparatus for locating tumors
US5284153A (en) 1992-04-14 1994-02-08 Brigham And Women's Hospital Method for locating a nerve and for protecting nerves from injury during surgery
US5333609A (en) * 1992-05-19 1994-08-02 Minnesota Mining And Manufacturing Company Catheter and probe-catheter assembly
IT1260485B (en) 1992-05-29 1996-04-09 PROCEDURE AND DEVICE FOR THE TREATMENT OF THE OBESITY OF A PATIENT
US5387231A (en) 1992-07-21 1995-02-07 Sporer; Patsy Electrotherapy method
JP3273066B2 (en) 1992-08-20 2002-04-08 オリンパス光学工業株式会社 Biological insertion tool
US5391143A (en) 1993-03-12 1995-02-21 Kensey Nash Corporation Method and system for effecting weight reduction of living beings
EP0706418A1 (en) * 1993-06-30 1996-04-17 Diametrics Medical Ltd. Biphasic material
EP0688578B1 (en) 1994-06-24 1999-11-10 Pacesetter AB Arrhythmia detector
US5891084A (en) * 1994-12-27 1999-04-06 Lee; Vincent W. Multiple chamber catheter delivery system
JP3930052B2 (en) 1996-02-15 2007-06-13 バイオセンス・インコーポレイテッド Catheter-based surgery
US5865744A (en) 1996-09-16 1999-02-02 Lemelson; Jerome H. Method and system for delivering therapeutic agents
US5655548A (en) 1996-09-16 1997-08-12 Circulation, Inc. Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion
US5817138A (en) 1996-11-27 1998-10-06 Suzuki; James Y. Multi-channel, interferential wave, micro current device and methods for treatment using micro current
US6026326A (en) 1997-01-13 2000-02-15 Medtronic, Inc. Apparatus and method for treating chronic constipation
US6272370B1 (en) 1998-08-07 2001-08-07 The Regents Of University Of Minnesota MR-visible medical device for neurological interventions using nonlinear magnetic stereotaxis and a method imaging
US6015414A (en) 1997-08-29 2000-01-18 Stereotaxis, Inc. Method and apparatus for magnetically controlling motion direction of a mechanically pushed catheter
US7066924B1 (en) 1997-11-12 2006-06-27 Stereotaxis, Inc. Method of and apparatus for navigating medical devices in body lumens by a guide wire with a magnetic tip
US20030113303A1 (en) 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
US6024704A (en) 1998-04-30 2000-02-15 Medtronic, Inc Implantable medical device for sensing absolute blood pressure and barometric pressure
AU3973599A (en) 1998-05-08 1999-11-29 Genetronics, Inc. Electrically induced vessel vasodilation
WO1999065561A1 (en) 1998-06-19 1999-12-23 Cordis Webster, Inc. Method and apparatus for transvascular treatment of tachycardia and fibrillation
DE19843408C2 (en) 1998-09-22 2000-10-26 Siemens Ag Method for reproducing x-ray images when positioning a catheter inserted into a vessel and device for carrying out the method
US7076307B2 (en) 2002-05-09 2006-07-11 Boveja Birinder R Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders
US6611715B1 (en) 1998-10-26 2003-08-26 Birinder R. Boveja Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator
US6366814B1 (en) 1998-10-26 2002-04-02 Birinder R. Boveja External stimulator for adjunct (add-on) treatment for neurological, neuropsychiatric, and urological disorders
US6115637A (en) 1998-12-22 2000-09-05 Universities Research Association, Inc. Microcurrent therapeutic technique for treatment of radiation toxicity
US6106477A (en) 1998-12-28 2000-08-22 Medtronic, Inc. Chronically implantable blood vessel cuff with sensor
US20010041870A1 (en) 1999-03-09 2001-11-15 Edward M. Gillis Implantable device for access to a treatment site
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
AU770243B2 (en) 1999-04-09 2004-02-19 Evalve, Inc. Methods and apparatus for cardiac valve repair
US6895278B1 (en) 1999-04-14 2005-05-17 Transneuronix, Inc. Gastric stimulator apparatus and method for use
US6606523B1 (en) 1999-04-14 2003-08-12 Transneuronix Inc. Gastric stimulator apparatus and method for installing
US6542776B1 (en) 1999-04-14 2003-04-01 Transneuronix Inc. Gastric stimulator apparatus and method for installing
US6684104B2 (en) 1999-04-14 2004-01-27 Transneuronix, Inc. Gastric stimulator apparatus and method for installing
US6692490B1 (en) 1999-05-18 2004-02-17 Novasys Medical, Inc. Treatment of urinary incontinence and other disorders by application of energy and drugs
US6587719B1 (en) 1999-07-01 2003-07-01 Cyberonics, Inc. Treatment of obesity by bilateral vagus nerve stimulation
US6368274B1 (en) 1999-07-01 2002-04-09 Medtronic Minimed, Inc. Reusable analyte sensor site and method of using the same
US6804558B2 (en) 1999-07-07 2004-10-12 Medtronic, Inc. System and method of communicating between an implantable medical device and a remote computer system or health care provider
US20040102804A1 (en) 1999-08-10 2004-05-27 Chin Albert K. Apparatus and methods for endoscopic surgical procedures
DE19958408A1 (en) 1999-12-02 2001-06-07 Philips Corp Intellectual Pty Magnetic resonance arrangement with devices to localize or visualize instrument inserted in patient; has magnet device controlled and positioned by control unit, to vary position in MRI datasets
JP2001187035A (en) 1999-12-28 2001-07-10 Tanita Corp Lesion recovery degree judging device
US6826428B1 (en) 2000-04-11 2004-11-30 The Board Of Regents Of The University Of Texas System Gastrointestinal electrical stimulation
DE10018334C1 (en) 2000-04-13 2002-02-28 Implex Hear Tech Ag At least partially implantable system for the rehabilitation of a hearing impairment
AU2001255713A1 (en) 2000-04-25 2001-11-07 Harumi Naganuma Noninvasive detection and activation of the lymphatic system in treating diseaseand alleviating pain
DE10020846A1 (en) 2000-04-28 2001-12-06 Intelligent Implants Gmbh Micro-contact structure for neuroprostheses for implantation on nerve tissue and method therefor
US6584362B1 (en) 2000-08-30 2003-06-24 Cardiac Pacemakers, Inc. Leads for pacing and/or sensing the heart from within the coronary veins
US20020029037A1 (en) 2000-09-06 2002-03-07 Kim Young D. Method and apparatus for percutaneous trans-endocardial reperfusion
US20020072780A1 (en) 2000-09-26 2002-06-13 Transneuronix, Inc. Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity
US6615084B1 (en) 2000-11-15 2003-09-02 Transneuronix, Inc. Process for electrostimulation treatment of morbid obesity
US6950707B2 (en) 2000-11-21 2005-09-27 Advanced Bionics Corporation Systems and methods for treatment of obesity and eating disorders by electrical brain stimulation and/or drug infusion
US6609025B2 (en) 2001-01-02 2003-08-19 Cyberonics, Inc. Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation
US7519421B2 (en) 2001-01-16 2009-04-14 Kenergy, Inc. Vagal nerve stimulation using vascular implanted devices for treatment of atrial fibrillation
US7179251B2 (en) * 2001-01-17 2007-02-20 Boston Scientific Scimed, Inc. Therapeutic delivery balloon
EP1377335B1 (en) 2001-02-06 2007-10-10 Medtronic Vascular, Inc. Apparatus for guided transluminal interventions using vessel wall penetrating catheters and other apparatus
ITBO20010110A1 (en) 2001-03-01 2002-09-01 Tre Esse Progettazione Biomedi PROCEDURE AND IMPLANTABLE DEVICE FOR THE INTRA-PULMONARY MEASUREMENT OF PHYSICAL PROPERTIES OF THE PULMONARY FABRIC DEPENDENT ON ITS DENSIT
US7167751B1 (en) 2001-03-01 2007-01-23 Advanced Bionics Corporation Method of using a fully implantable miniature neurostimulator for vagus nerve stimulation
ITMI20010684A1 (en) 2001-03-30 2002-09-30 Valerio Cigaina DEVICE AND PROCEDURE FOR CHECKING THE ENTITY OF THE INTRA-ABDOMINAL FAT
US7083593B2 (en) * 2001-04-18 2006-08-01 Advanced Bionics Corporation Programmable implantable pump with accessory reservoirs and multiple independent lumen catheter
US6535764B2 (en) 2001-05-01 2003-03-18 Intrapace, Inc. Gastric treatment and diagnosis device and method
US20020188253A1 (en) 2001-06-07 2002-12-12 Pharmaspec Corporation Method and apparatus for drug delivery in veins
US20040158297A1 (en) 2001-06-29 2004-08-12 George Gonzalez Process for testing and treating motor and muscle function, sensory, autonomic, cognitive and neurologic disorders
US6685729B2 (en) 2001-06-29 2004-02-03 George Gonzalez Process for testing and treating aberrant sensory afferents and motors efferents
US6735477B2 (en) 2001-07-09 2004-05-11 Robert A. Levine Internal monitoring system with detection of food intake
US6678557B1 (en) 2001-08-20 2004-01-13 Tvx Internet Services, Inc. System and method for body fat management
US6974448B2 (en) * 2001-08-30 2005-12-13 Medtronic, Inc. Method for convection enhanced delivery catheter to treat brain and other tumors
US6893429B2 (en) * 2001-08-30 2005-05-17 Medtronic, Inc. Convection enhanced delivery catheter to treat brain and other tumors
US7734355B2 (en) 2001-08-31 2010-06-08 Bio Control Medical (B.C.M.) Ltd. Treatment of disorders by unidirectional nerve stimulation
US6970741B1 (en) 2001-09-18 2005-11-29 Advanced Bionics Corporation Monitoring, preventing, and treating rejection of transplanted organs
WO2003028542A2 (en) 2001-10-02 2003-04-10 Arthrocare Corporation Apparatus and methods for electrosurgical removal and digestion of tissue
US6934583B2 (en) 2001-10-22 2005-08-23 Pacesetter, Inc. Implantable lead and method for stimulating the vagus nerve
US6575971B2 (en) 2001-11-15 2003-06-10 Quantum Cor, Inc. Cardiac valve leaflet stapler device and methods thereof
US6961621B2 (en) 2001-12-04 2005-11-01 Cardiac Pacemakers, Inc. Apparatus and method for stabilizing an implantable lead
US20030144708A1 (en) 2002-01-29 2003-07-31 Starkebaum Warren L. Methods and apparatus for retarding stomach emptying for treatment of eating disorders
US7551964B2 (en) 2002-03-22 2009-06-23 Leptos Biomedical, Inc. Splanchnic nerve stimulation for treatment of obesity
US7689276B2 (en) 2002-09-13 2010-03-30 Leptos Biomedical, Inc. Dynamic nerve stimulation for treatment of disorders
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US20040015201A1 (en) 2002-04-22 2004-01-22 Transneuronix, Inc. Process for electrostimulation treatment of obesity
US20030204185A1 (en) 2002-04-26 2003-10-30 Sherman Marshall L. System and method for monitoring use of disposable catheters
US7862513B2 (en) 2002-05-14 2011-01-04 Pacesetter, Inc. Apparatus for minimally invasive calibration of implanted pressure transducers
US20040193229A1 (en) 2002-05-17 2004-09-30 Medtronic, Inc. Gastric electrical stimulation for treatment of gastro-esophageal reflux disease
US7769427B2 (en) 2002-07-16 2010-08-03 Magnetics, Inc. Apparatus and method for catheter guidance control and imaging
EP1551498A1 (en) 2002-07-26 2005-07-13 Transneuronix, Inc. Improved process for electrostimulation treatment of morbid obesity
JP2004065529A (en) 2002-08-06 2004-03-04 Takayuki Sato Blood pressure controlling apparatus
US7901419B2 (en) 2002-09-04 2011-03-08 Allergan, Inc. Telemetrically controlled band for regulating functioning of a body organ or duct, and methods of making, implantation and use
US6918873B1 (en) 2002-09-19 2005-07-19 Millar Instruments, Inc. Inverted sensor module
EP1551505B1 (en) 2002-10-04 2010-02-24 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
US7986994B2 (en) 2002-12-04 2011-07-26 Medtronic, Inc. Method and apparatus for detecting change in intrathoracic electrical impedance
US7452334B2 (en) 2002-12-16 2008-11-18 The Regents Of The University Of Michigan Antenna stent device for wireless, intraluminal monitoring
WO2004064918A1 (en) 2003-01-14 2004-08-05 Department Of Veterans Affairs, Office Of General Counsel Cervical wagal stimulation induced weight loss
US7167750B2 (en) 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US7250041B2 (en) 2003-03-12 2007-07-31 Abbott Cardiovascular Systems Inc. Retrograde pressure regulated infusion
US20040210118A1 (en) 2003-04-18 2004-10-21 Michel Letort In situ detection of endoleak and endotension
US7620454B2 (en) 2003-05-19 2009-11-17 Medtronic, Inc. Gastro-electric stimulation for reducing the acidity of gastric secretions or reducing the amounts thereof
US7295877B2 (en) 2003-07-31 2007-11-13 Biosense Webster, Inc. Encapsulated sensor with external antenna
US20050043669A1 (en) * 2003-08-18 2005-02-24 Codman & Shurtleff, Inc. Trimmable sensing catheter
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
US8346482B2 (en) 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
US7632234B2 (en) 2003-08-29 2009-12-15 Medtronic, Inc. Implantable biosensor devices for monitoring cardiac marker molecules
US20050070974A1 (en) 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
US20050075702A1 (en) 2003-10-01 2005-04-07 Medtronic, Inc. Device and method for inhibiting release of pro-inflammatory mediator
US7418292B2 (en) 2003-10-01 2008-08-26 Medtronic, Inc. Device and method for attenuating an immune response
US7194301B2 (en) * 2003-10-06 2007-03-20 Transneuronic, Inc. Method for screening and treating patients at risk of medical disorders
US7200443B2 (en) 2003-10-07 2007-04-03 John Faul Transcutaneous electrical nerve stimulator for appetite control
US7054690B2 (en) 2003-10-22 2006-05-30 Intrapace, Inc. Gastrointestinal stimulation device
CA2536188A1 (en) 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
EP1706170A4 (en) * 2003-12-12 2010-03-24 Philometron Inc Multiple section parenteral drug delivery apparatus
WO2005062823A2 (en) 2003-12-19 2005-07-14 Savacor, Inc. Digital electrode for cardiac rhythm management
US7203540B2 (en) 2003-12-22 2007-04-10 Cardiac Pacemakers, Inc. Method and system for setting cardiac resynchronization therapy parameters
WO2005072793A1 (en) 2004-01-29 2005-08-11 The Charles Stark Draper Laboratory, Inc. Implantable drug delivery apparatus
US7366572B2 (en) 2004-03-16 2008-04-29 Medtronic, Inc. Controlling therapy based on sleep quality
US20050222637A1 (en) 2004-03-30 2005-10-06 Transneuronix, Inc. Tachygastrial electrical stimulation
US20050222638A1 (en) 2004-03-30 2005-10-06 Steve Foley Sensor based gastrointestinal electrical stimulation for the treatment of obesity or motility disorders
US20070244520A1 (en) 2004-04-19 2007-10-18 Searete Llc Lumen-traveling biological interface device and method of use
US8545414B2 (en) 2004-04-30 2013-10-01 St. Jude Medical, Cardiology Division, Inc. Methods and devices for modulation of heart valve function
GB0409769D0 (en) 2004-04-30 2004-06-09 Algotec Ltd Electrical nerve stimulation device
EP2422751A3 (en) 2004-05-05 2013-01-02 Direct Flow Medical, Inc. Unstented heart valve with formed in place support structure
JP2008501037A (en) 2004-06-01 2008-01-17 マイクロチップス・インコーポレーテッド Devices and methods for measuring and enhancing transport of drugs or analytes to / from medical implants
US7803195B2 (en) 2004-06-03 2010-09-28 Mayo Foundation For Medical Education And Research Obesity treatment and device
US7596413B2 (en) 2004-06-08 2009-09-29 Cardiac Pacemakers, Inc. Coordinated therapy for disordered breathing including baroreflex modulation
US20060074453A1 (en) 2004-10-04 2006-04-06 Cvrx, Inc. Baroreflex activation and cardiac resychronization for heart failure treatment
US20070027460A1 (en) 2005-07-27 2007-02-01 Cook Incorporated Implantable remodelable materials comprising magnetic material
US20070027484A1 (en) 2005-07-28 2007-02-01 Cyberonics, Inc. Autonomic nerve stimulation to treat a pancreatic disorder
US7532935B2 (en) 2005-07-29 2009-05-12 Cyberonics, Inc. Selective neurostimulation for treating mood disorders
US7774055B1 (en) 2005-11-07 2010-08-10 Pacesetter, Inc. Left atrial pressure-based criteria for monitoring intrathoracic impedance
US20070163353A1 (en) 2005-12-07 2007-07-19 Drexel University Detection of blood pressure and blood pressure waveform
US7606622B2 (en) 2006-01-24 2009-10-20 Cardiac Pacemakers, Inc. Method and device for detecting and treating depression
EP1981584B1 (en) 2006-02-03 2015-05-13 Interventional Autonomics Corporation Intravascular device for neuromodulation
JP5322917B2 (en) 2006-03-15 2013-10-23 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Use of gelsolin for the diagnosis and treatment of inflammatory diseases
US7881797B2 (en) 2006-04-25 2011-02-01 Valentx, Inc. Methods and devices for gastrointestinal stimulation
US7761166B2 (en) 2006-04-28 2010-07-20 Medtronic, Inc. Electrical stimulation of iliohypogastric nerve to alleviate chronic pelvic pain
US7809441B2 (en) 2006-05-17 2010-10-05 Cardiac Pacemakers, Inc. Implantable medical device with chemical sensor and related methods
US7526337B2 (en) 2006-06-06 2009-04-28 Cardiac Pacemakers, Inc. Method and device for lymphatic system monitoring
US8126538B2 (en) 2006-06-06 2012-02-28 Cardiac Pacemakers, Inc. Method and apparatus for introducing endolymphatic instrumentation
US7894906B2 (en) 2006-06-06 2011-02-22 Cardiac Pacemakers, Inc. Amelioration of chronic pain by endolymphatic stimulation
US20070282376A1 (en) 2006-06-06 2007-12-06 Shuros Allan C Method and apparatus for neural stimulation via the lymphatic system
US7734341B2 (en) 2006-06-06 2010-06-08 Cardiac Pacemakers, Inc. Method and apparatus for gastrointestinal stimulation via the lymphatic system
US8905999B2 (en) 2006-09-01 2014-12-09 Cardiac Pacemakers, Inc. Method and apparatus for endolymphatic drug delivery
US7664548B2 (en) 2006-10-06 2010-02-16 Cardiac Pacemakers, Inc. Distributed neuromodulation system for treatment of cardiovascular disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030036773A1 (en) * 2001-08-03 2003-02-20 Whitehurst Todd K. Systems and methods for treatment of coronary artery disease
WO2004032791A2 (en) * 2002-09-20 2004-04-22 Flowmedica, Inc. Method and apparatus for selective material delivery via an intra-renal catheter
EP1504778A2 (en) * 2003-08-06 2005-02-09 Ethicon Endo-Surgery Implantable pump for the treatment of obesity

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7734341B2 (en) 2006-06-06 2010-06-08 Cardiac Pacemakers, Inc. Method and apparatus for gastrointestinal stimulation via the lymphatic system
US7894906B2 (en) 2006-06-06 2011-02-22 Cardiac Pacemakers, Inc. Amelioration of chronic pain by endolymphatic stimulation
US8126538B2 (en) 2006-06-06 2012-02-28 Cardiac Pacemakers, Inc. Method and apparatus for introducing endolymphatic instrumentation
US8369943B2 (en) 2006-06-06 2013-02-05 Cardiac Pacemakers, Inc. Method and apparatus for neural stimulation via the lymphatic system
US8897878B2 (en) 2006-06-06 2014-11-25 Cardiac Pacemakers, Inc. Method and apparatus for gastrointestinal stimulation via the lymphatic system
US8905999B2 (en) 2006-09-01 2014-12-09 Cardiac Pacemakers, Inc. Method and apparatus for endolymphatic drug delivery
US10376694B2 (en) 2008-10-09 2019-08-13 Virender K. Sharma Method and apparatus for stimulating the vascular system
US10603489B2 (en) 2008-10-09 2020-03-31 Virender K. Sharma Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage
US11517749B2 (en) 2008-10-09 2022-12-06 Virender K. Sharma Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage
WO2023076259A1 (en) 2021-10-25 2023-05-04 Revere Pharmaceuticals Triazolopyridazine compounds useful as rac1 inhibitors

Also Published As

Publication number Publication date
US20080097412A1 (en) 2008-04-24
US8905999B2 (en) 2014-12-09
JP4987082B2 (en) 2012-07-25
JP2010502274A (en) 2010-01-28
EP2076307B1 (en) 2012-02-15
ATE545445T1 (en) 2012-03-15
WO2008030344A3 (en) 2008-05-15
EP2076307A2 (en) 2009-07-08
AU2007293445A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
EP2076307B1 (en) Implantable apparatus for endolymphatic drug delivery
US8126538B2 (en) Method and apparatus for introducing endolymphatic instrumentation
US7894906B2 (en) Amelioration of chronic pain by endolymphatic stimulation
US7532938B2 (en) Intraluminal electrode assembly
US7526337B2 (en) Method and device for lymphatic system monitoring
CA2356032C (en) Shunt
EP1396233B1 (en) Positioning system for neurological procedures in the brain
US20080108904A1 (en) Implant for securing a sensor in a vessel
US6328699B1 (en) Permanently implantable system and method for detecting, diagnosing and treating congestive heart failure
EP2968881B1 (en) Apparatus for delivery of medication to the brain to treat neurological conditions
JP2021529602A (en) Magnetic Resonance Imaging Convection Convection Enhanced Delivery Cranial Implant Device and Related Methods
US11344210B2 (en) Delivery catheter for implantable medical device
US10695484B1 (en) Systems and methods for lumbar cerebrospinal fluid access and treatment
CN104825150A (en) Intracranial disease monitoring and treating device
US10687794B2 (en) Delivery catheter for implantable medical device

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837256

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007293445

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009526646

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007293445

Country of ref document: AU

Date of ref document: 20070823

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007837256

Country of ref document: EP